Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Sem 5 > Pharmacology 4: Diabetes and obesity > Flashcards

Pharmacology 4: Diabetes and obesity Flashcards

1
Q

tment which must be given immediately for diabetic ketoacidosis?

A

insulin-IV at a fixed rate for DKA
rehydration- IV replacement fluids, with K+ in fluid as insulin drives K+ into cells via Na+/H+ exchange stimulation and subsequent increased Na+ pump activity, so patient would otherwise become hypokalaemic very quickly, putting them at risk of cardiac arrythmias.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

classes of oral hypoglycaemic drugs?

A

those which increase sensitivity to insulin (insulin sensitisers): biguanides e.g. metformin, thiazolineinediones (glitazones) e.g. pioglitazone.
those which stimulate insulin release: sulfonylureas e.g. tolbutamide and glipizide, and meglitinides e.g. nateglinide.
glucagon like peptide-1 analogues
dipeptidyl peptidase-4 (DPP4) inhibitors (gliptins)
alpha-Glucosidase inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

how do thiazolineinediones (glitazones) work?

A

agonsitically bind to peroxisome proliferator-activated receptor-gamma (PPAR-gamma)= transcription factor- regulates AT differentiation and role in lipid met., which binds with another nuclear receptor- retinoid X receptor, complex upregulates wide set of genes- in liver, SM and AT, with products important in insulin signalling and so increase insulin sensitivity in AT and muscle.
increase glucose uptake
reduce glucose synthesis in liver, muscle and AT
suppress hepatic gluconeogenesis, and so reduce hepatic glucose output

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

how do sulfonylureas work?

A

antagonise beta cell K+/ATP channel activity, causing decrease in K+ current, which cause depolarisation, which then increases Ca2+ entry into cell, which governs fusion rate of insulin vesicles with beta cell membrane, and their release into circulation.
Meglitidines also work in this way.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Orlistat is a drug used to treat obesity, how does it work?

A

gastric and pancreatic lipase inhibitor, so reduces dietary fat conversion to FA and glycerol for absorption.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

SEs of orlistat?

A

soft fatty stools, flatus, unpleasant faecal discharge or faecal incontinence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Sibutramine is used to treat obesity, how does it work?

A

NA and serotonin (5-HT) reuptake inhibitor. Suppresses appetite anf some additional reduction in hyperglycaemia rate of glucose met, poss. due to increased thermogenesis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

SEs of sibutramine

A

increase HR and BP- CVS risk factors present and being treated in obese diabetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

example of drug used to delay carbohydrate absorption by gut?

A

alpha-glucosidase inhibitors e.g. acarbose- inhibits bdown of carbohydrates to glucose
SEs: runny stools, flatulence- as carbs fermented by gut bacteria, abdominal pain, diarrhoea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

effects of insulin in body, other than decreasing blood glucose levels?

A

STORAGE promotion hormone

  • stimulates hepatic glycogen prod via increasing glucokinase activity, glycolysis, and inhibits glycogenolysis and gluconeogenesis
  • stimulates hepatic FA synthesis-for transport as lipoproteins- increase circulating free FA, promote clearance of circulating free FA
  • inhibition of fat b.down in hepatocytes (lipolysis)- lipase inhibition
  • increase aa uptake by muscle
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

3 modes of action of metformin?

A

increase sensitivity of cells to insulin, and so stimulates glucose uptake by AT and skeletal muscle
inhibits hepatic gluconeogenesis
reduced absorption of glucose from gut

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

describe the process of insulin production

A

synthesised initially as preproinsulin- exported into ER where signal peptide cleaved by signal peptidase, to create proinsulin- folds via disulphide bond formation and is transported to secretory vesicles where cleavage via endopeptidase produces insulin (A and B peptides with 2 S-S bridges) and C peptide= released in endogenous amounts from secretory vesicle.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

how is insulin secretion by pancreatic beta cells stimulated by increased glucose?

A

glucose met. increases IC ATP/ADP ratio.
glucose enters beta cells via GLUT2 transporter- facilitated diffusion, enters glycolytic pathway after conversion to glucose 6-phosphate by hexokinase. increase ATP closes K+/ATP sensitive channel, causing cell depolarisation, Ca2+ influx and fusion of insulin vesicles with cell membrane.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

why is insulin secretion prevented by low blood glucose?

A

low ATP:ADP in pancreatic beta cells as low glucose met, which opens K+/ATP channel, maintaining cells in a hyperpolarised state that prevents Ca2+ influx.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

how does insulin act on it target tissues e.g. AT, muscle and liver?

A

via a tyrosine-kinase linked receptor: binds to EC domain and activates TK, causing autophosphorylation of tyrosine and phosphorylation of intracellular insulin receptor substrate proteins. These protiens recruit 2nd messenger proteins important for insulin action.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

how is glucose reabsorbed by the kidneys and how is the process affected in diabetes?

A

PCT: high-capacity, low-affinity Na+-glucose co-transporter= SGLT2 on apical membrane= secondary AT using Na+ gradient generated by Na+K+ATPase, generates conc gradient for glucose that allows facilitated diffusion across BL membrane via GLT2.
straight PT: high affinity, low-capacity 2Na+-glucose co-transporter (SGLT1), GLT1 on BL membrane.
diabetes= excess glucose filtered, renal threshold exceeded so excess glucose unable to be reabsorbed and is excreted in urine. Glucose increase osmolarity of filtrate, reducing H20 reabsorption- remains with glucose and is excreted.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

renal threshold for glucose?

A

200mg/100ml

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

despite high glucose in type 1 diabetes, why do glycogenolysis and gluconeogenesis proceed unchecked?

A

unavailability of insulin to promote glucose uptake into tissues, coupled with unopposed actions of counter-regulatory hormones e.g. cortisol and glucagon- increase PEPCK and fructose 1,6-bisphosphatase activity, causing starvation like response.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

how does obesity link to insulin resistance?

A

insulin receptor desensitisation
ectopic accumulation of lipid into liver and muscle
obesity-induced inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

how does insulin suppress appetite?

A

insulin and leptin stimulate the inhibitory primary neurone that releases POMC to inhibit appetite, and inhibit the stimulatory pathway where NPY and agouti-related peptide are released to stimulate appetite.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

only aspect of insulin functioning which differs depending on which insulin you give to a patient?

A

rate of insulin absorption into blood following SC injection, which depends on insulin solubility and local circulation
this is dependent on aa sequence
formulation of drug different, can use recombinant DNA technology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

why might insulin requirement in an individual need to be increasef?

A

stress
infection
trauma
during puberty

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

what insulin regimen may be suitable for a patient who has 3 meals a day at fixed times/structured lifestyle?

A

a twice daily insulin regimen/conventional insulin therapy: you will inject twice a day, once before breakfast and once before dinner, a mixture of a shorter acting insulin and intermediate acting insulin, and the shorter acting may be either short acting insulin or a rapid acting insulin.

24
Q

what insulin regimen may be suitable for a patient who doesn’t have fixed meal times?

A

a basal-bolus regimen: involves taking a longer acting form of insulin once or twice daily to keep blood glucose levels stable through periods of fasting and separate injections of shorter acting insulin to prevent rises in blood glucose levels resulting from meals. so basal taken= long or intermediate acting insulin, and bolus with every meal- short or rapid acting insulin. Tries to replicate how a non-diabetic person’s body releases insulin, and involves number of insulin injection throughout day. Can eat when you want.

25
Q

when are sulfonylureas e.g. gliclazide considered in type II diabetic patients?

A

patients who are not overweight, and in whom metformin is contra-indicated e.g. resp disease, compromised HRH function, or not tolerated. (mainly met in liver so can be used in renal failure patients.)
can be used if patient acutely unwell

26
Q

why should glibenclamide be avoided in the elderly?

A

long acting sulfonyurea- assoc with greater risk of hypoglycaemia (elderly- more at risk of this, eat less, and reduced drug met- PKs altered?)

27
Q

cautions with sulfonylurea administration?

A

elderly
obese patients- metformin= drug of choice
G6PDD patients- risk of excessive haemolysis

28
Q

ADRs with sulfonylureas?

A 
hypoglycaemia
weight gain
GI disturbances: diarrhoea and constipation
hyponatraemia
hypersensitivity reactions
29
Q

when are glitazones used in type 2 DM?

A

NICE (May 2009) has recommended that, when glycaemic control is inadequate with existing treatment, pioglitazone can be added to:
a sulfonylurea, if metformin is contra-indicated or not tolerated;

metformin, if risks of hypoglycaemia with sulfonylurea are unacceptable or a sulfonylurea is contra-indicated or not tolerated;

a combination of metformin and a sulfonylurea, if insulin is unacceptable because of lifestyle or other personal issues, or because the patient is obese.

30
Q

ADRs of glitazones?

A

weight gain
oedema- so contraindicated in HF patients
fractures in post-menopausal women, increased OP risk as inhibit bone formation
risk of bladder cancer- so must check for haematuria
increased LDLs and HDLs- rosiglitazone no longer used as led to CVD events

*drugs also high cost

31
Q

3 main tissues insulin acts upon?

A

liver
skeletal muscle
adipose tissue

32
Q

describe why insulin given to diabetics is associated with weight gain?

A

in type 2 diabetics, insulin resistance typically more severe in muscle and liver compared with AT, so insulin preferentially deposits calories in AT, causing weight gain.
AT: insulin causes increased glucose uptake, lipogenesis and esterification of FA, and increase lipoprotein lipase activity in capillary bed for FA uptake.

33
Q

why are drugs for diabetes characterised by having low therapeutic indexes (TD50/ED50)?

A

to keep balance between hyper and hypo glycaemia

34
Q

4 types of insulin available with recombinant DNA technology?

A

human short acting
human rapid acting analogues
isophane intermediate acting insulin
long acting basal analogues

aa structure modified to affect absorption

35
Q

adverse effects of insulin?

A

hypoglycaemia
hyperglycaemia
lipodystrophy- hypertrophy or atrophy at injection site**
painful injections
insulin allergies- type IV (delayed) hypersentivity reactions may occur, can change brand of insulin as will be a different formulation in terms of preservative used

36
Q

give 2 important factors as to why diabetics may not be compliant with treatment?

A

risk/perceived risk of hypoglycameia

weight gain/fear of weight gain

37
Q

general HbA1c target in all type 2 diabetics?

A

6.5-7.5 %

38
Q

despite insulin have the greatest potential for lowering HbA1c, what is its main limitation?

A

risk of hypoglycaemia

39
Q

advantages of using metformin in type 2 diabetes?

A

little weight gain, may even be weight loss
reduces LDLs and VLDLs- reduces CVS events
cheap- £8-10 annually
doesn’t induce hypoglycaemia
can use slow release (extended absorption) to help cope with GI symptoms, but this is more expensive
1-2% HbA1c lowering potential
can be used in stage III CKD, but stopped once eGFR<30ml/min, or significant comorbidities

40
Q

conditions other than type 2 diabetes in which metformin may be used?

A

PCOS- reduces insulin resistance, balances androgens and oestrogens
anti-cancer- breast and bowel?

41
Q

advantages of using sulfonylureas?

A

1-2% HbA1c lowering potential
cheap
mainly metabolised via liver, so can be used in renal impairment
can be used if patients acutely unwell

42
Q

ADRs of metformin?

A

lactic acidosis
reduced vit B12 absorption
GI disturbances: diarrhoea, abdominal pain
taste disturbance

43
Q

ADRs of acarbose?

A 
runny, loose stools
abdominal pain
abdominal distension
flatulence
diarrhoea
44
Q

effects of glucagon like peptide-1 (GLP-1) in body?

A

released from intestinal L cells and it:
increases is insulin secretion
reduces glucagon secretion
increases insulin biosynthesis
increases satiety, so reduces food intake
reduces gastric emptying
increases glucose uptake in muscle and reduces glucose prod. by liver

45
Q

mechanism of action of gliptins (DPP-4 inhibitors) e.g. sitagliptin, saxagliptin?

A

inhibit breakdown of glucagon like peptide-1 so increase post-prandial concentrations of GLP-1, which increases insulin release and reduces glucagon release, so there is increased glucose uptake, and reduced glucose output from the liver.

46
Q

advantages of gliptin use?

A

weight neutral
low risk of hypoglycaemia
modest HbA1c reduction

47
Q

ADRs of gliptins?

A 
GI disturbances
peripheral oedema
URTIs
headache
possible pancreatitis
48
Q

NICE guidelines on gliptins?

A

consider adding 2nd line to metformin or sulfonylurea with HbA1c >6.5% if:
patient at significant risk of hypoglycaemia and its consequences e.g. elderly, living alone
patient doesn’t tolerate sulfonylurea, or CI
can be used as triple therapy
continue only if HbA1c reduction > or equal to 0.5% is achieved and maintained over 6 mnths

49
Q

ADRs of GLP-1 agonists e.g. exenatide?

A

GI symptoms- diarrhoea, nausea, loose stools
GO reflux
occasionally painful to inject
?pancreatitis

but low risk of hypoglycaemia

50
Q

NICE guidelines on exenatide?

A

continue only if HbA1c reduction of 1% or more at 6 mnths

and weight loss of at least 3% at 6 mnths

51
Q

action of glifozins e.g. dapaglifozin?

A

insulin-independent approach to remove excess glucose

inhibit SGLT2 in PCT- so inhibit glucose reabsorption

52
Q

ADRs of glifozins?

A

increase risk of lower UT symptoms e.g. genital and UTIs
polyuria
hypoglycaemia

BUT weight neutral, and may promote weight loss

53
Q

define hypoglycaemia and list its clinical signs

A

plasma glucose concentration of less than or equal to 3mmol/L
similar signs to someone intoxicated with alcohol
include slurring of speech, confusion, drowsiness, weakness, trembling, sweating, nausea, tingling around lips, palpitations, staggering walk

54
Q

general dietary advice for diabetic patients?

A

– include high-fibre, low-glycaemic- index sources of carbohydrate
– include low-fat dairy products and oily fish – control the intake of foods containing saturated fats and trans fatty acids.
-Limited substitution of sucrose- containing foods for other carbohydrate is allowable, but care should be taken to avoid excess energy intake.
- Discourage use of foods marketed
specifically for people with diabetes

55
Q

how should HbA1c be monitored in diabetics?

A

2-6mnthly until stable on unchanging therapy

then 6 mnthly when blood glucose levels and blood glucose lowering therapy stable

56
Q

when might a sulfonylurea be considered rather than metformin for type 2 DM tment?

A

metformin CI e.g. heptic, renal or CVS dysfunction, or resp disease
patient not overweight
rapid therapeutic response required due to hyperglycaemic symptoms

Sem 5 (35 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions